Using patient data from the METABRIC and BeatAML studies (see Methods for details), we further showed that AGR2 upregulation is predictive of poor survival in ER-positive breast cancer patients, and that SRGN upregulation is associated with AML prognosis (Fig. 8). This evidence concerns the gene AGR2 and acute myeloid leukemia.